Ibrutinib
About
Therapy type: Targeted therapy
Therapy strategy: BTK inhibition
Mappings
NCI Thesaurus: Ibrutinib (coding:ncit:C81934)
RxNorm: ibrutinib (coding:rxcui:1442981, coding:omop:44507848)
SNOMED: Ibrutinib (coding:sctid:710228002, coding:omop:46271948)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| HSE (1) | TP53 Somatic variants | Chronic Lymphocytic Leukemia | Ibrutinib | |
| HSE (1) | TP53 deletion | Chronic Lymphocytic Leukemia | Ibrutinib | |
| FDA (1) HSE (1) | not 17p deletion | Chronic Lymphocytic Leukemia | Ibrutinib | |
| HSE (1) | t(11;14) | Mantle Cell Lymphoma | Ibrutinib | |
| HSE (1) | CCND1 | Mantle Cell Lymphoma | Ibrutinib |